refined this paradigm by identifying an inflamed subtype, SCLC-I, which is characterized by the concurrent loss of ASCL1, NEUROD1, and POU2F3 expression and a prominent immune signature (35). Here, NEUROD1 is linked to small cell lung carcinoma.